Clareo Health | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants, greater than or equal to (\>/=) 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
Met diagnostic-positive status tested by immunohistochemistry (IHC)
Results of endothelial growth factor receptor (EGFR)-activating mutation testing
Radiographic evidence of disease
Prior treatment with at least one platinum-based line of treatment (for stage IIIb/IV) and no more than one additional line of chemotherapy treatment; the last dose of chemotherapy must have been administered \>/= 21 days prior to Day 1
availability of tissue sample for diagnostic testing is required
You may not be if
More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications (EGFR inhibitors including but not limited to gefitinib, erlotinib and cetuximab)
Brain metastases or spinal cord compression not definitively treated with surgery and/or radiation, or previously treated central nervous system (CNS) metastases or spinal cord compression without evidence of stable disease for \>/= 14 days
History of another malignancy in the previous 3 years, unless cured by surgery alone and continuously disease free for at least 3 years; participants with prior history of non-invasive cancers are eligible
Inadequate hematological, biochemical or organ function
Significant history of cardiac disease
Serious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatment
Any inflammatory changes of the surface of the eye
Clinically significant gastro-intestinal disease, including uncontrolled inflammatory gastro-intestinal diseases
Pregnant or lactating women
Positive for human immunodefinciency (HIV) infection
